Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402CB | ISIN: US0453962070 | Ticker-Symbol: V7B
Tradegate
28.03.25
21:19 Uhr
10,000 Euro
+0,140
+1,42 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASSEMBLY BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ASSEMBLY BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,6409,88013:04
9,70010,00028.03.

Aktuelle News zur ASSEMBLY BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFY2029 Earnings Estimate for ASMB Issued By HC Wainwright62
20.03.Assembly Biosciences files for $250 mixed securities shelf94
20.03.Assembly Biosciences GAAP EPS of -$6.69 beats by $0.18, revenue of $28.52M beats by $0.31M54
20.03.ASSEMBLY BIOSCIENCES, INC. - 10-K, Annual Report10
ASSEMBLY BIOSCIENCES Aktie jetzt für 0€ handeln
20.03.Assembly Biosciences, Inc.: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights168- Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline - - Interim Phase 1b proof-of-concept data, including initial efficacy...
► Artikel lesen
26.02.Assembly Biosciences initiates phase 1a trial for HDV treatment candidate43
26.02.Assembly Biosciences startet Phase-1a-Studie für HDV-Behandlungskandidat121
26.02.Assembly Biosciences, Inc.: Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus262- Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 - - Biomarker of ABI-6250 target engagement, serum bile acids...
► Artikel lesen
20.02.ASSEMBLY BIOSCIENCES, INC. - 8-K, Current Report50
20.02.Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial101
20.02.Assembly Bio advances herpes treatment into next trial phase55
20.02.Assembly Biosciences, Inc.: Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes247- ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose...
► Artikel lesen
03.01.ASSEMBLY BIOSCIENCES, INC. - 8-K, Current Report104
02.01.Hedge Fund and Insider Trading News: Glenn Greenberg, Warren Buffett, Bill Ackman, D.E. Shaw, Millennium Management, Assembly Biosciences Inc (ASMB), Simon Property Group Inc (SPG), and More274
31.12.24Assembly Biosciences-Direktor Houghton kauft Aktien im Wert von 49.997 US-Dollar197
26.12.24Assembly Bio spikes after early-stage data for Gilead-partnered Hep B therapy88
26.12.24Assembly Biosciences reports positive phase 1b HBV drug results15
26.12.24Assembly Biosciences meldet positive Ergebnisse aus Phase-1b-Studie für HBV-Medikament119
26.12.24Assembly Biosciences, Inc.: Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B560- ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed - - In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity...
► Artikel lesen
26.12.24ASSEMBLY BIOSCIENCES, INC. - 8-K, Current Report8
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,8